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ABSTRACT
Introduction: In a previously published study,
vildagliptin showed a reduced risk of
hypoglycemia versus glimepiride as add-on
therapy to metformin at similar efficacy.
Glimepiride was titrated from a starting dose
of 2 mg/day to a maximum dose of 6 mg/day. It
is usually assumed that the increased
hypoglycemia with glimepiride was driven by
the 6 mg/day dose; it was therefore of interest to
assess whether the risk of hypoglycemia is also
different between vildagliptin and a low (2 mg/
day) dose of glimepiride.
Methods: Data (n = 3,059) were from the
aforementioned randomized, double-blind
study. Comparisons between vildagliptin
(50 mg twice daily) and glimepiride (subgroups
of patients on 2 mg/day, 6 mg/day, and ‘other’,
and overall glimepiride group) were done by
modeling hypoglycemia risk as a function of
time and last-measured glycated hemoglobin
(HbA1c) using discrete event time modeling,
with treatment, age, gender as additional
covariates.
Results: The hypoglycemia risk was
significantly lower in patients receiving
vildagliptin versus patients remaining on
glimepiride 2 mg/day throughout the study,
with similar results unadjusted or adjusted for
last HbA1c [adjusted hazard ratio (HR) = 0.06
(95% CI 0.03, 0.11)]. The risk of hypoglycemia
was very low with vildagliptin over the full
HbA1c range, while the risk with glimepiride
2 mg/day increased with lower HbA1c. The
increase for lower levels of HbA1c was more
pronounced in the glimepiride 2 mg/day than
6 mg/day subgroup, with the 6 mg/day
subgroup showing the lowest hypoglycemia
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risk among the glimepiride groups [adjusted HR
vildagliptin vs. 6 mg/day glimepiride = 0.21
(95% CI 0.11, 0.40)].
Conclusion: The data show a substantially
lower risk of confirmed hypoglycemia with
vildagliptin compared to low-dose (2 mg/day)
glimepiride. The analysis indicates that the
previously reported results are not driven by
high doses of glimepiride and points to
interesting differences among patients
regarding the susceptibility to hypoglycemia
with sulfonylureas.
Keywords: Dipeptidyl peptidase-4;
Hypoglycemia; Sulfonylurea; Type 2 diabetes;
Vildagliptin
INTRODUCTION
Hypoglycemia is a common problem in patients
with type 2 diabetes mellitus (T2DM), occurring
most frequently with anti-hyperglycemic
treatments increasing insulin levels
independently of the blood glucose level, such
as oral insulin secretagogues [sulfonylureas
[SUs] and glinides] and exogenous insulin.
Hypoglycemia is associated with multiple
adverse consequences that may, in some cases,
counterbalance the benefit of strict glycemic
control. Importantly, hypoglycemia is
recognized as a major limiting factor for
achieving intensive glycemic control in people
with T2DM [1, 2] and makes clinicians less
likely to implement glycemic targets [3].
Hypoglycemia is also often associated with
weight gain due to decreased adherence to diet
with ‘‘defensive eating’’ to prevent and/or
correct hypoglycemia [4]. Furthermore, severe
hypoglycemic events have been associated with
an increased risk of cardiovascular
complications and death [5, 6]. Lastly,
episodes of hypoglycemia reduce adherence to
therapy as well as quality of life [7] and lead to
increased medical costs [8].
Unlike indiscriminate insulin secretagogues,
such as SUs and glinides, dipeptidyl peptidase-4
(DPP-4) inhibitors regulate glucose homeostasis
in a glucose-dependent manner and are,
consequently, associated with a low risk of
hypoglycemia [9]. In addition to the glucose-
dependent secretion of insulin and glucagon
common to all incretin-based therapies,
preservation of glucagon counter-regulation to
hypoglycemia has been specifically shown for
the DPP-4 inhibitor vildagliptin in several
mechanistic studies and is likely a glucose-
dependent insulinotropic polypeptide-
mediated effect [9–12].
Clinically, the risk of hypoglycemia was
compared between vildagliptin and the SU
glimepiride as add-on therapy to metformin in
a large, randomized, double-blind study
evaluating patients with well-controlled T2DM,
but not having reached target, thus being at
increased risk for hypoglycemia with additional
glucose-lowering therapy [13, 14]. In this study,
patients treated with metformin (*1,900 mg/
day) and a mean baseline glycated hemoglobin
(HbA1c) of 7.3% were randomized to receive
either vildagliptin (50 mg twice daily [bid]) or
glimepiride (titrated up to 6 mg/day), with data
analyzed after 1 year (interim analysis;
n = 2,789) [13] and 2 years (n = 3,118) [14].
While the efficacy was comparable between the
two treatment arms––non-inferiority established
at both timepoints––vildagliptin was associated
with significant reductions in the frequency and
severity of hypoglycemia. Over 1 year, confirmed
hypoglycemia was reported in 1.7% of
vildagliptin-treated patients (39 events)
compared with 16.2% of glimepiride-treated
patients (554 events, P\0.01), with 0 vs. 10
severe events (P\0.01) [13]. Similar results were
also seen after 2 years, with 2.3% vs. 18.2% of
460 Diabetes Ther (2014) 5:459–469
patients, respectively, experiencing
hypoglycemia, and a 14-fold difference in the
number of events [14].
Given that glimepiride in the study could be
titrated from a starting dose of 2 mg/day to a
maximum dose of 6 mg/day, a potential
limitation of the study was the perception that
the hypoglycemia difference might be driven by
high doses of glimepiride, although it is not
known whether the risk of hypoglycemia
during treatment with glimepiride is dose
dependent. The purpose of the present
analysis was, therefore, to compare the risk of
confirmed hypoglycemia with vildagliptin to
the subgroup of glimepiride-treated patients
remaining on the dose of 2 mg/day
throughout the study. In addition, the study
provided the opportunity to assess the
hypoglycemia risk of patients tolerating
different dose levels of the SU to explore the
potential dose dependency of the risk of
hypoglycemia for glimepiride. Since
differences in HbA1c, in particular during the
initial 24 weeks of the study where glimepiride
was somewhat more efficacious than
vildagliptin [13], could have contributed to
the difference in hypoglycemia risk between
the two treatments, and hypoglycemia is a
particular barrier in the lower HbA1c range for
achieving glycemic targets, the hypoglycemia
potential of the two drugs was assessed in
relation to the HbA1c level.
METHODS
Patients and Study Design
Data from the aforementioned and previously
published, multicenter, randomized, double-
blind study comparing vildagliptin and
glimepiride were used for this analysis [13, 14].
In this study, patients with T2DM on stable
treatment with metformin and HbA1c of
6.5–8.5% were randomized 1:1 to receive
vildagliptin 50 mg bid or glimepiride for
104 weeks. Glimepiride was started at a dose of
2 mg/day and could be up-titrated to a
maximum of 6 mg/day.
Assessments
Hypoglycemia was defined as symptoms
suggestive of low blood glucose confirmed by
self-monitored blood glucose (SMBG)
measurement \3.1 mmol/L plasma glucose
equivalent. HbA1c was measured regularly in
the study and analyzed by a central laboratory
(Covance Central Laboratory Services).
Data Analysis
The total number of patients and demography/
baseline characteristics are presented for the
vildagliptin group, the glimepiride 2 mg/day,
6 mg/day and ‘other’ subgroups, and the overall
glimepiride group for the intent-to-treat (ITT)
population.
The glimepiride subgroups were defined as
follows: the 2 mg/day subgroup included all
patients who remained on glimepiride 2 mg/
day throughout their entire study duration; the
6 mg/day subgroup included all patients who
were either up-titrated to 6 mg/day by week 16
latest and subsequently stayed on this dose level
throughout the remainder of their study
duration or discontinued up to week 16 with
6 mg/day as their last dose; and the ‘other’
subgroup consisted of all remaining
glimepiride-treated patients.
The reported post hoc analysis was done in the
ITT population using discrete event–time
modeling [15], following the approach in a
recently published paper [16]. Hypoglycemic
risk was modeled as a function of time and last-
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measured HbA1c, with treatment (or subgroup)
and gender included as additional covariates. All
hazard ratios (HRs) were estimated from this
model, with the unadjusted hazard rates
ignoring last-measured HbA1c as a covariate.
Further details are presented in ESM Appendix 1.
While all data over the entire study duration
were used in the modeling, it was chosen to
predict the hypoglycemia risk for week 24 as the
minimum duration of most standard clinical
trials is 24 weeks and it falls into the main
period where the SU was somewhat more
efficacious than vildagliptin [13]. In addition,
this time point ensured a more robust
assessment compared with the later stages of
the study when an increasing number of
discontinuations occurred.
Mean changes from baseline in HbA1c at
week 24 in the vildagliptin group, the different
glimepiride subgroups and the overall
glimepiride group were analyzed using last
observation carried forward in the ITT
population. Within-group comparisons
(endpoint vs. baseline) were made using one
sample t test at a significance level of 0.05.
Ethics and Good Clinical Practice
All study participants provided written informed
consent. The protocol was approved by the
independent ethics committee/institutional
review board at each study site or country. The




Table 1 summarizes the demographic and
baseline characteristics of patients in the
vildagliptin 50 mg bid (n = 1,539), glimepiride
2 mg/day (n = 417), glimepiride 6 mg/day
(n = 589), glimepiride ‘other’ (n = 514) and
overall glimepiride (n = 1,520) groups. The
demographic and baseline characteristics were
overall comparable across the vildagliptin and
glimepiride groups (Table 1). The patients
studied in the different groups had a mean age
of 56–59 years, 53–54% were men and the vast
majority (82–91%) were Caucasian. Mean HbA1c
was 7.0–7.5%, mean body mass index was
31–32 kg/m2 and mean duration of diagnosed
T2DM was 5–6 years, with a mean duration of
metformin use of 2.8–3.1 years (mean dose
1,853–1,902 mg/day). More than two-thirds of
patients (64–73%) had normal renal function
and renal impairment was predominantly mild
in the remaining patients.
Risk of Confirmed Hypoglycemia
The analysis showed that the risk of confirmed
hypoglycemia was significantly lower in
patients treated with vildagliptin 50 mg bid
compared with patients who remained on
glimepiride 2 mg/day for their entire study
duration (2 mg/day subgroup), with similar
results unadjusted [HR = 0.04 (95% CI 0.02,
0.08); P\0.0001] or adjusted for last-measured
HbA1c [HR = 0.06 (95% CI 0.03, 0.11);
P\0.0001]. As shown in Fig. 1, the risk of
hypoglycemia was very low with vildagliptin
over the full HbA1c range while the risk with
glimepiride 2 mg/day increased with lower
HbA1c. The increase for lower levels of HbA1c
was more pronounced in the glimepiride 2 mg/
day subgroup than in the full set of patients
treated with glimepiride (Fig. 1). The HR of
vildagliptin versus the overall glimepiride
group was 0.07 [(95% CI 0.04, 0.13);
P\0.0001] unadjusted and 0.08 [(95% CI
0.05, 0.15); P\0.0001] adjusted for last-
measured HbA1c.
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To further assess the hypoglycemia risk of
patients on different dose levels of glimepiride,
in addition to the low-dose (2 mg/day)
subgroup, analyses were also performed for the
high-dose (6 mg/day) subgroup and the ‘other’
subgroup (comprising all remaining
glimepiride-treated patients). As shown in
Fig. 2, among the glimepiride groups, the
2 mg/day subgroup had the highest increase in
hypoglycemia risk for lower levels of HbA1c,
while this increase in hypoglycemia risk was
least pronounced in the 6 mg/day subgroup.
The ‘other’ subgroup had an intermediate risk,
although the difference between the 2 mg/day
subgroup and the ‘other’ subgroup was small.
The HR of vildagliptin versus 6 mg/day
glimepiride was 0.22 [(95% CI 0.12, 0.43);
P\0.0001] unadjusted and 0.21 [(95% CI
0.11, 0.40); P\0.0001] adjusted for last-
measured HbA1c, and this was 0.06 [(95% CI
0.03, 0.10); P\0.0001] and 0.07 [(95% CI 0.04,
0.12); P\0.0001], respectively, for the
glimepiride ‘other’ subgroup.
Changes in HbA1c
While the hypoglycemia analyses were adjusted
for last-measured HbA1c, for completeness,
changes in HbA1c were also evaluated.
Figures 1 and 2 show the hypoglycemia risk as
predicted for week 24 (see ‘‘Methods’’ for
details); for comparison, changes in HbA1c
were assessed at week 24. In each group, a
highly significant mean change in HbA1c from
baseline to week 24 was observed. The decreases
in HbA1c were -0.5 ± 0.02% (baseline 7.3%) in
the vildagliptin 50 mg bid group, -0.6 ± 0.03%
(baseline 7.0%) in the glimepiride 2 mg/day
subgroup, -0.7 ± 0.03% (baseline 7.5%) in the
glimepiride 6 mg/day subgroup, -0.7 ± 0.03%
Fig. 1 Risk of conﬁrmed hypoglycemia as a function of
the most recently measured glycated hemoglobin (HbA1c)
in patients with type 2 diabetes mellitus after treatment
with vildagliptin 50 mg bid ? metformin (solid line;
n = 1,539), glimepiride ‘overall’ ? metformin (dashed
line; n = 1,520) or glimepiride 2 mg/day ? metformin
(dotted line; n = 417). Risks are shown for week 24
[intent-to-treat (ITT) population]
Fig. 2 Risk of conﬁrmed hypoglycemia as a function of
the most recently measured glycated hemoglobin (HbA1c)
in patients with type 2 diabetes mellitus after treatment
with glimepiride 6 mg/day ? metformin (open diamond;
n = 589), glimepiride ‘‘other’’ ? metformin (dash dotted
line; n = 514) or glimepiride 2 mg/day ? metformin
(dotted line; n = 417). Risks are shown for week 24
[intent-to-treat (ITT) population]
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(baseline 7.3%) in the glimepiride ‘other’
subgroup and -0.7 ± 0.02% (baseline 7.3%) in
the overall glimepiride group (P\0.0001 vs.
baseline in all groups). Thus, the week 24
endpoint mean HbA1c was \7% (6.4–6.8%) in
all groups.
DISCUSSION
In a previously published study (mean HbA1c
7.3%), vildagliptin (50 mg bid) showed a
markedly reduced risk of hypoglycemia
compared with glimepiride as add-on therapy
to metformin at similar efficacy [13, 14].
However, since glimepiride was titrated from a
starting dose of 2 mg/day to a maximum dose of
6 mg/day, one limitation of the trial was the
perception that the SU dose was titrated to too
high doses and the hypoglycemia difference
was driven by the highest glimepiride dose of
6 mg/day. The present analysis, however,
clearly showed a substantially lower risk of
confirmed hypoglycemia with vildagliptin
when compared with low-dose (2 mg/day)
glimepiride. In addition, while all glimepiride
subgroups showed a higher risk than the
vildagliptin group, among the glimepiride
groups the hypoglycemia risk was, against
common perception, more pronounced in the
glimepiride 2 mg/day subgroup than in the
glimepiride 6 mg/day subgroup. Thus, the
previously reported hypoglycemia results were
not driven by high doses of glimepiride and an
inverse relationship between the glimepiride
dose and hypoglycemia risk was observed.
An additional limitation of the original study
concerned the possibility that differences in
HbA1c reductions/levels of HbA1c in particular
during the initial 24 weeks of the study, where
glimepiride was somewhat more efficacious
than vildagliptin [13], could have contributed
to the difference in hypoglycemia risk between
vildagliptin and glimepiride. In the present
analysis, the hypoglycemia risk was, therefore,
assessed in relation to the last-measured HbA1c
level using discrete event–time modeling. The
reduced risk of hypoglycemia with vildagliptin
versus glimepiride remained essentially
unchanged when adjusted for the most
recently measured HbA1c level, as seen from
the very similar HRs unadjusted and adjusted
for all groups of glimepiride. Hence, it is
unlikely that differences in hypoglycemic risk
between the two groups can be attributed to
differences in HbA1c reductions. The analysis
further showed that, as expected, the difference
between the two treatments increased with
increasingly lower HbA1c levels. A limitation
remains that the most recently measured HbA1c
value associated with the hypoglycemic event
was used in the analysis, while the HbA1c at the
time of the hypoglycemia event was usually not
available. The adjustment for last-measured
HbA1c was also relevant when comparing the
hypoglycemia risk between the glimepiride
groups as it needs to be acknowledged that the
baseline HbA1c level was somewhat lower in the
glimepiride 2 mg/day subgroup than the
glimepiride 6 mg/day subgroup; on the other
hand, the glycemic levels were very low in all
subgroups, so that the small differences could
not have been expected to drive a major
difference in hypoglycemia risk.
While the difference in hypoglycemia risk
between vildagliptin and glimepiride manifests
independent of the dose level, the at-first-
glance unexpected finding of an inverse
relationship between the glimepiride dose and
hypoglycemia risk seen in the present
assessment merits further comment. A
potential explanation could be linked to the
known attenuation of glucagon counter-
regulation seen in T2DM [17]; it seems
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reasonable to assume that this impairment in
glucagon counter-regulation varies among
patients secondary to a progressive reduction
in the sensitivity of the a-cell to glucose. In
addition, there is a variable amount of residual
glucose-sensitive insulin secretion among
different patients. The progression of T2DM is
associated with a progressive decline in b-cell
function/sensitivity [18], the degree of this loss
varies between different patients and some
individuals have very little remaining b-cell
glucose sensitivity [19]. In patients with more
residual b-cell sensitivity to glucose on top of
the SU-induced glucose-independent insulin
secretion, there is a faster postprandial b-cell
response to increase insulin secretion, followed
by a faster b-cell response to reduce insulin
secretion when glucose levels fall [20, 21]. Thus,
patients, who have lost much of their ability to
secrete both insulin and glucagon in a glucose-
sensitive manner, can be expected to be more
susceptible to hypoglycemia induced by
medications that stimulate insulin secretion in
a glucose-independent manner. Consequently,
such patients would have been more likely to
have their glimepiride dose restricted to the
lowest dose level of 2 mg/day in the study
underlying the present analysis and even at
this dose they would still have a higher risk of
hypoglycemia compared with other patients
with more residual glucose sensitivity. The
latter patients would consequently also be
more likely to tolerate high doses of SUs,
which could provide an explanation for the
lower hypoglycemia risk observed in the 6 mg/
day subgroup compared with the 2 mg/day
subgroup in the present analysis. Interestingly,
a similar observation was previously made in a
double-blind study comparing gliclazide
modified release (MR; titrated from 30 mg/day
to a maximum of 120 mg/day) and glimepiride
(titrated from 1 mg/day to a maximum of 6 mg/
day) [22], suggesting that this could be a general
finding with SUs. In both treatment groups,
most hypoglycemic events occurred at the two
lowest treatment doses (representing *51% of
the study population); of 22 events with
gliclazide MR, there were 13 and 2 events with
the 30 mg and 60 mg dose, respectively, and of
56 events with glimepiride, there were 21 and
27 events with the 1 mg and 2 mg doses,
respectively [22]. While patients who are less
susceptible to hypoglycemia under SU
treatment obviously exist, a clear limitation in
clinical practice is that it is not possible to
predict which patients are more or less sensitive,
unless they are actually exposed to SU
treatment and potential hypoglycemia to
determine their hypoglycemia risk. In
addition, while some patients may start with a
lower risk of hypoglycemia with SUs, it is not
clear what will happen over time as T2DM
progresses and islet cell function further
deteriorates.
In contrast to the SUs that stimulate insulin
secretion in a glucose-independent manner,
increase insulin capacity even at low glucose
concentrations [23, 24] and can significantly
impair glucagon counter-regulation (as shown
for both tolbutamide and glibenclamide) [25,
26], DPP-4 inhibitors, such as vildagliptin, have
been shown to stimulate insulin secretion and
inhibit glucagon secretion in a glucose-
dependent manner [9]. In addition, at
hypoglycemic levels, preserved glucagon
counter-regulation has been explicitly
demonstrated for vildagliptin in several studies
and patient groups [10, 11, 27]. These effects
underlie the low propensity of vildagliptin to
cause hypoglycemia, even at low levels of
glycemia and across different patient groups
and disease states [9, 28, 29].
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CONCLUSION
Taken together, the data show a substantially
lower risk of confirmed hypoglycemia with
vildagliptin compared with low-dose (2 mg/
day) glimepiride and also reveal an inverse
relationship between glimepiride dose and
hypoglycemia risk. Thus, the additional
analyses presented here further extend the
knowledge/understanding on the differences
between vildagliptin and the SU glimepiride
with respect to the risk of hypoglycemia and
point to interesting differences among patients
with T2DM regarding the susceptibility to
hypoglycemia with SUs.
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